Compounds · Skin & hair · Treatment of erythropoietic protoporphyria and photosensitivity disorders
Afamelanotide
Melanotan I, MT-I, CUV1647, Scenesse
Synthetic α-MSH analog approved (Scenesse) for erythropoietic protoporphyria, a rare light-sensitivity disorder. Boosts eumelanin production to extend pain-free sun exposure.
0.25 mg twice weekly, then weekly
Research score 85/100. Reference only, not a prescription.
- Skin Health
- Melanin Production
- Photoprotection
- Pain Relief
- Anti-inflammatory
- US status
- FDA Approved
- Approval
- FDA + EMA Approved
- Evidence
- FDA approved (Scenesse) for EPP. Implant delivery.
- Research score
- 85 / 100
- Indication
- Photoprotection
- Origin
- Australia
- Source category
- Skin & Dermatology
- Status group
- Approved / prescription
Mechanism
Agonizes melanocortin-1 receptors on melanocytes, raising cAMP and driving MITF-linked tyrosinase activity toward eumelanin over pheomelanin. Also curbs NF-κB-driven inflammation and supports DNA-repair and antioxidant responses.
Safety file
Implant-site reactions are common, along with nausea, headache, and darkened skin. Anaphylaxis is rare.
- Nausea
- Headache
- Skin darkening
- Injection site reactions
- Fatigue
Important: The only approved form of afamelanotide is Scenesse, a 16 mg implant placed by a clinician every 2 months for a rare light-sensitivity disorder (EPP). Injectable Melanotan-1 is unapproved; the protocol below is community practice, not a label.
Reconstitution
| Vial | 1 mL water | 2 mL water |
|---|---|---|
| 10 mg | 10 mg/mL | 5 mg/mL |
- Use bacteriostatic water as the diluent.
- Add the water slowly, letting it run down the inside wall of the vial rather than onto the powder.
- Swirl gently to mix, then leave it to dissolve. Do not shake.
- Give it a few minutes. The finished solution should be clear and colourless.
Protocol
Route: Subcutaneous
Standard protocol (subcutaneous)
- Loading: 0.25 mg (250 mcg) twice weekly for about 4 weeks, paired with gradual UV exposure (15 to 30 minutes, building up)
- Maintenance: taper to roughly once weekly once colour develops
- At a 2 mL fill on a 10 mg vial (5 mg/mL), 0.25 mg is a 0.05 mL draw (5 units)
Milder than Melanotan-2
- Melanotan-1 (afamelanotide) causes much less nausea and does not have the libido or appetite effects of MT-2, so most people tolerate it more easily
Dosing detail
- Loading: 0.25 mg twice weekly for about 4 weeks. Maintenance: about once weekly after colour develops.
- Pair with gradual UV exposure to build the tan.
- Reported as milder than MT-2. The Scenesse label lists nausea, headache, dizziness, fatigue and new moles.
- Watch moles and freckles for any changes, as with any tanning peptide.
Duration
- About 4 weeks of twice-weekly loading, then weekly maintenance.
Notes
- Also called afamelanotide. Milder on nausea and without the libido effect of MT-2.
- The Scenesse label advises a full-body skin check twice a year.
- Inject subcutaneously and rotate sites.
Storage and handling
- Keep the powdered (lyophilized) vial in a cool, dark place. Refrigerate it for longer-term storage before mixing.
- Once reconstituted and refrigerated at 2–8 °C away from light, use the vial within 28 days.
- Do not freeze a reconstituted vial, and keep it away from heat and sunlight.
- If the solution turns cloudy, develops floating particles, or shows any other sign of degradation, stop using that vial.